News

  1. Home
  2. News

PolyBio-supported study uncovers plasma signatures associated with long COVID respiratory symptoms

Medford MA, April 28, 2025 — A new PolyBio-supported study published today in Nature Immunology sheds light on the biological underpinnings...

PolyBio-supported study reveals long-term immune and metabolic damage after COVID-19 infection

New preprint study reveals profound and long-lasting biological disruptions that can follow a SARS-CoV-2 infection, including changes connected to altered metabolism...

Chan Soon-Shiong Family Foundation donation expands PolyBio Long COVID program

Funds will support exploration of SARS-CoV-2’s potential to drive cancer, as well as continued work delineating persistence of the virus in...

PolyBio’s Message to Science Innovators: Curbing Persistent Infection is Great Challenge of Our Times

Medford, Mass., April 7 2025 – Dr. Amy Proal’s participation in two recent major conferences on scientific innovation highlighted a growing...

Cutting-edge Recommendations Provide Treatment Path for Millions of Long COVID Patients

In a new report, global experts outline key considerations to address persistent SARS-CoV-2; provide a roadmap to test critical new long...

New research illuminates link between chronic infection and Alzheimer’s Disease, paving the way for potential antiviral treatment

A new study published in Nature Communications has unveiled a crucial connection between chronic infection with Cytomegalovirus (HCMV), and the development...

PolyBio-supported study first to document dysfunctional natural killer cells in long COVID

PolyBio-supported study finds reduced percentages of cytotoxic natural killer cells in people with long COVID. The immune dysfunction might facilitate SARS-CoV-2...

New grant to PolyBio further expands long COVID blood biomarker study

For the second consecutive year, funding will expand a Harvard Medical School-based project documenting immune, coagulation, and blood vessel abnormalities in...

PolyBio supports & helps conceptualize long COVID rapamycin clinical trial

The trial will test a low dose of the drug rapamycin in participants across a 3-month period. Analysis of participant blood...

PolyBio/Mount Sinai collaborators open state-of-the-art center for patients with Long COVID and related conditions

PolyBio’s support for the clinic includes development of innovative clinical trials, a “clean air” technology infrastructure, and a continued focus on...

$1M PolyBio donation will expand UCSF LIINC study to ME/CFS

Advanced technologies will be used to study critically important – yet understudied – biological factors in ME/CFS patients whose illness began...

“Multiple hit” model shows that COVID protein potentiates subsequent infection-related neuroinflammation and other physiological problems

PolyBio-supported study in rats demonstrates that SARS-CoV-2 protein activity drives longer-term vulnerability to another infection, augmenting physiological problems such as neuroinflammation,...

Newsletter

PolyBio scientists are active at conferences and frequent guests on podcasts. Learn more about these events, get project updates, and meet the PolyBio team via our Newsletter.

Sign Up